Enhabit (EHAB) Q4 2025 earnings review
Kinderhook Acquisition Caps Off a Year of Operational Turnaround
Enhabit's fourth quarter results confirm that its 2025 turnaround strategy succeeded, culminating in a definitive agreement to be acquired by Kinderhook Industries for $13.80 per share in cash (a ~$1.1 billion enterprise value). The company delivered accelerating consolidated revenue growth (+4.7% YoY) and steady Adjusted EBITDA improvement, fueled by aggressive non-Medicare expansion and a relentless focus on deleveraging. While Medicare Fee-for-Service volumes continue to shrink and Hospice margins saw sudden compression, the operational stabilization achieved over the last four quarters provided the foundation for a clean exit from public markets. Because of the pending merger, guidance and the Q4 earnings call have been suspended.
🐂 Bull Case
The $13.80 per share cash acquisition by Kinderhook neutralizes the looming threat of the destructive 2026 CMS Home Health rate cuts that previously overshadowed the stock.
The company reduced bank debt by another $15 million in Q4, bringing the net leverage ratio down to 3.7x from 4.9x a year ago. Consistent free cash flow generation unlocked $125 million in total debt reduction over the past two years.
🐻 Bear Case
After quarters of robust margin expansion, Hospice segment Adjusted EBITDA margin compressed to 21.4% in Q4 (down from 23.0% YoY and 27.3% in Q3), hampered by a 14.1% spike in General & Administrative expenses.
The core, high-margin Medicare Home Health business remains in a structural decline, with Q4 average daily census down 4.0% YoY and revenues falling 4.9% YoY.
⚖️ Verdict: 🟢
Bullish. While some underlying segment margins showed stress, management successfully executed the two most vital tasks of 2025: shifting the Home Health payer mix to offset Medicare declines, and aggressively paying down debt. This operational discipline culminated in a successful premium buyout.
Key Themes
Kinderhook Acquisition Secures an Exit
The dominant theme of Q4 is the definitive Merger Agreement with Kinderhook Industries. Valued at roughly $1.1 billion, the deal promises $13.80 per share in cash to stockholders. Slated to close in Q2 2026, the transaction allows Enhabit to pivot away from the public market glare right as substantial CMS Medicare rate cuts threaten the broader Home Health industry. This effectively caps the company's standalone investment narrative.
Relentless Deleveraging Yields Results
Enhabit's balance sheet repair strategy has been highly effective. The company executed its eighth straight quarter of debt prepayments, retiring $15 million in Q4 2025. By shedding $125 million in bank debt since Q4 2023, management secured $22 million in annualized cash interest savings. The leverage ratio is now stable at 3.7x, dramatically improving the enterprise's financial flexibility prior to the merger announcement.
Non-Medicare Growth Offsets Traditional FFS Declines
The Home Health segment's pivot to non-Medicare payers is accelerating. Non-Medicare admissions surged 16.0% YoY in Q4, driving a 15.6% increase in non-Medicare revenue to $93.4 million. This robust volume bridged the gap left by traditional Medicare admissions, which declined 4.0%. The strategic pursuit of 'payer innovation' episodic contracts has successfully returned the segment to top-line growth (+3.2% overall).
Medalogix Deployment Sharpens Operational Efficiency
Enhabit is successfully wringing clinical capacity out of its existing workforce. Driven by the deployment of the Medalogix Pulse technology, visits per Home Health episode dropped precipitously from 14.3 in 24Q4 to 12.9 in 25Q4 (-9.8%). This allowed the company to reduce its cost per patient day by 3.5% YoY to $27.8, even as the raw cost per individual visit rose 7.1% to $102 due to labor inflation.
Hospice Margins Reversing Direction
Hospice has been the reliable growth engine for the past year, but Q4 showed a reversing profitability trend. Despite average daily census growing an impressive 9.9% YoY, segment Adjusted EBITDA only rose 2.3%. Gross margins held steady, but a 14.1% YoY surge in segment General & Administrative expenses pushed the Adjusted EBITDA margin down to 21.4% (from 23.0% a year prior).
Heavy Goodwill Impairment Muddies the Bottom Line
Enhabit's GAAP Net Loss of $38.7 million in Q4 was primarily driven by a substantial $44.7 million impairment of goodwill (and a $3.0 million intangible asset impairment). While these are non-cash charges that management excludes from Adjusted EPS, they underscore the historical overvaluation of certain legacy assets prior to the successful turnaround.
De Novo Expansion Resumes Steady Pace
The company continues to sow seeds for organic volume capacity, opening 4 de novo locations in Q4 2025 to bring the full-year total to 10. These new branches provide a self-sustaining pipeline for new admissions, particularly vital in the Hospice segment where facility maturation directly correlates to census density.
Other KPIs
Accelerating significantly from $0.04 in the prior year quarter. The massive gap between reported GAAP EPS (-$0.76) and Adjusted EPS ($0.14) is largely attributable to the $44.7 million goodwill impairment charge recorded during Q4.
Stable improvement, up slightly from 48.5% in 24Q4. The Home Health segment achieved 47.7% (up from 47.4%), offsetting minor weakness in the Hospice segment (down to 52.0% from 52.2%).
Stable. The discharged average length of stay remained perfectly flat year-over-year at 110 days, indicating that the strong 9.9% growth in average daily census is coming from sheer volume and successful admission conversions rather than patients artificially lingering on the service longer.
Guidance
Because of the pending acquisition by Kinderhook Industries announced in February 2026, Enhabit management is formally suspending all forward-looking financial guidance.
Key Questions
Merger Regulatory Hurdles
What, if any, regulatory or antitrust approvals do you anticipate could delay or complicate the closing of the Kinderhook acquisition currently slated for Q2 2026?
Hospice G&A Inflation
Hospice segment General and Administrative expenses spiked 14.1% YoY this quarter, compressing segment margins. Was this driven by one-time investments in sales teams or de novo branch overhead, or is this a structural shift in the cost base?
Standalone Fallback Plan
In the unlikely event the merger is terminated, are the previously discussed mitigation strategies (like the Medalogix VPE reduction pilot) sufficient to entirely offset the proposed 2026 CMS Home Health rate cuts on a standalone basis?